Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient With Metastatic Gastric Adenocarcinoma

Nivolumab is a humanized monoclonal anti-programmed cell death receptor-1 (PD-1) antibody that has been authorized for use in the treatment of advanced malignancies. Cutaneous reactions are the most common immune-related adverse events reported with anti-PD-1 agents, and they range broadly from mild...

Descripción completa

Detalles Bibliográficos
Autores principales: Saad, Eltaib, Adhikari, Pabitra, Antala, Drashti, Abdulrahman, Ahmed, Begiashvili, Valiko, Mohamed, Khalid, Ali, Elrazi, Zhang, Qishou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534193/
https://www.ncbi.nlm.nih.gov/pubmed/36258702
http://dx.doi.org/10.14740/jmc3992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534193/
https://www.ncbi.nlm.nih.gov/pubmed/36258702
http://dx.doi.org/10.14740/jmc3992

Ejemplares similares